2012 SASL 联合特拉泼韦或博赛泼韦的三联疗法治疗基因1型慢性丙型肝炎
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
2012-02-24
瑞士肝病研究协会2012年2月发布的关于三联疗法治疗基因1型慢性丙型肝炎的指南，该方案包含了目前国际推荐的直接抗HCV的蛋白酶抑制剂特拉泼韦或者博赛泼韦。Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitisC genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates to ~70% and allows to shorten treatment duration in ~½ of treatment-naïve patients with chronic hepatitisC genotype 1. Sustained virological response rates in treatment-experienced patients depend on the response to previous treatment, ranging from >80% in previous relapsers to ~30% in previous null responders. These advances come at the expense of new adverse effects and increased cost. In addition, treatment of chronic hepatitis C will become more complex. In these times of changing medical practice, the present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir.
